IP Library Granted Patent US 8,415,323
Granted Patent B2
US 8,415,323 · App. 12/675,368 · Granted Apr 9, 2013

MicroRNAs for inhibiting viral replication

Inventor: Michael David (San Diego, CA)
Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,415,323
App. No.
12/675,368
Granted
Apr 9, 2013
Kind
B2
Abstract

The present invention relates to reducing accumulation of viral genomes in a target cell. In particular the present invention provides compositions and methods for combating viral infection through RNA interference. Specifically the present invention provides cellular microRNA mimics for treating virus-infected subjects.

Claims (13)

1. A method for reducing accumulation of Hepatitis C virus RNA, comprising:

introducing a first isolated nucleic acid molecule into a Hepatitis C virus (HCV)-infected target cell in an amount sufficient for reducing accumulation of HCV RNA in said target cell, wherein said first isolated nucleic acid molecule is a miRNA mimic comprising the nucleotide sequence of a cellular microRNA selected from the group consisting of miR-196, miR-296, miR-351, miR-431 and miR-448.

2. The method of claim 1 , wherein said cellular microRNA is said miR-196 consisting of the nucleotide sequence set forth as SEQ ID NO:7.

3. The method of claim 1 , wherein said cellular microRNA is said miR-296 consisting of the nucleotide sequence set forth as SEQ ID NO:8.

4. The method of claim 1 , wherein said cellular microRNA is said miR-351 consisting of the nucleotide sequence set forth as SEQ ID NO:9.

5. The method of claim 1 , wherein said cellular microRNA is said miR-431 consisting of the nucleotide sequence set forth as SEQ ID NO:10.

6. The method of claim 1 , wherein said cellular microRNA is said miR-448 consisting of the nucleotide sequence set forth as SEQ ID NO:11.

7. The method of claim 1 , further comprising introducing a second isolated nucleic acid molecule into said HCV-infected target cell, wherein said second isolated nucleic acid molecule is an anti-miRNA comprising the nucleotide sequence complementary to miR-122.

8. The method of claim 7 , wherein said miR-122 consists of the nucleotide sequence set forth as SEQ ID NO:3.

9. The method of claim 1 , wherein said target cell is in vitro.

10. The method of claim 1 , wherein said target cell is in vivo.

11. The method of claim 10 , wherein said method comprises administering the first isolated nucleic acid molecule to a subject comprising said HCV-infected target cell.

12. The method of claim 1 , wherein said miRNA mimic is a mature miRNA.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 28, 2013
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030498/0581 →
CONFIRMATORY LICENSE Recorded Aug 5, 2011
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026705/0613 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2010
From: DAVID, MICHAEL
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 024700/0835 →
Continuity (2)
Provisional Application 60966411 · Aug 27, 2007
Related Publication 20100286240A1 · Nov 11, 2010